Literature DB >> 3041828

Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent.

J J Curtis1, R G Luke, P Jones, A G Diethelm.   

Abstract

PURPOSE: Physicians increasingly prescribe cyclosporine as an immunosuppressive agent for both organ-transplant and non-organ-transplant recipients. Investigators have reported a high incidence of drug-induced hypertension even when clinical nephrotoxicity was not present. We wanted to determine the reason. PATIENTS AND METHODS: A comparison was made of hypertension in 15 cyclosporine-treated transplant recipients with that in a similar group of 15 azathioprine-treated transplant recipients.
RESULTS: Hypertension in the cyclosporine group responded differently from that seen in the azathioprine group and from previously described forms of post-transplantation hypertension. Hypertensive cyclosporine-treated patients show a sodium acquisitive renal state that responds to sodium restriction. Unlike rat models, which suggest cyclosporine-induced stimulation of the renin-angiotensin system, or previous forms of post-transplant hypertension in humans, plasma renin levels were not elevated and blood pressure did not respond to a test dose of captopril.
CONCLUSION: Hypertension in cyclosporine-treated patients is an iatrogenic form of hypertension that may be associated with an early, subtle, renal defect in sodium excretion, a genesis of hypertension that is consistent with Guyton's view of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041828     DOI: 10.1016/s0002-9343(88)80331-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  President's address: salt-too much of a good thing?

Authors:  Robert G Luke
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

Review 2.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

3.  Cyclosporin A stimulates apical Na+/H+ exchange in LLC-PK1/PKE20 proximal tubular cells.

Authors:  Thomas Epting; Kathrin Hartmann; Anna Sandqvist; Roland Nitschke; Nader Gordjani
Journal:  Pediatr Nephrol       Date:  2006-05-11       Impact factor: 3.714

Review 4.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 5.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 6.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 7.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

8.  Hypertension after renal transplantation in patients treated with cyclosporin and azathioprine.

Authors:  N Gordjani; G Offner; P F Hoyer; J Brodehl
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

9.  Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol.

Authors:  Jing Wang; Zhi-Ren Zhang; Chu-Fang Chou; You-You Liang; Yuchun Gu; He-Ping Ma
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-17

10.  Triple immunosuppression with subsequent prednisolone withdrawal: 6 years' experience in paediatric renal allograft recipients.

Authors:  S M Chao; C L Jones; H R Powell; L Johnstone; D M Francis; G J Becker; R G Walker
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.